Biologists find new way to lower tumour risk in stem cell therapies

One of the characteristics of embryonic stem cells is their ability to form unusual tumours called teratomas.


Mice with dysfunctional immune systems that receive human embryonic stem cells produce tumors called teratomas.

These tumours, which contain a mixture of cells from a variety of tissues and organs of the body, are typically benign. But they present a major obstacle to the development of human embryonic stem cell therapies that seek to treat a variety of human ailments such as Parkinson's, diabetes, genetic blood disorders and spinal cord injuries.

Now a team of biologists at University of California at San Diego funded by a grant from the California Institute for Regenerative Medicine, the state's stem-cell funding agency, has discovered a way to limit the formation of teratomas.

In this week's issue of the Proceedings of the National Academy of Sciences, the researchers report that they have identified a new signalling pathway critical for unlimited self propagation of embryonic stem cells. Using small molecule compounds that inhibit this pathway, the scientists were able to dramatically reduce the potential of embryonic stem cells to form teratomas.

''Human stem cell therapy involves differentiating human embryonic stem cells into the kinds of cells needed for the treatment,'' said Yang Xu, a professor of biology who headed the team that published the report. ''But this differentiation is never complete, meaning that the final product is a mixture of cells inevitably containing undifferentiated embryonic stem cells. So by transplanting these cells into a patient, there's clearly a risk of producing teratomas.''